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ABSTRACT: Background. Radiotherapy (XRT) exerts detrimental collateral
effects on bone tissue through mechanisms of vascular damage and
impediments to osteocytes, ultimately predisposing patients to the debil-
itating problems of late pathologic fractures and nonunions. We posit
that angiogenic therapy will reverse these pathologic effects in a rat
model of radiated fracture healing.
Methods. Three groups of rats underwent mandibular osteotomy. Radi-
ated groups received a fractionated 35-Gy dose before surgery. The
deferoxamine (DFO) group received local injections postoperatively. A
40-day healing period was allowed before histology. Analysis of variance
(ANOVA; p< .05) was used for group comparisons.
Results. Radiated fractures revealed a significantly decreased osteocyte
count and corresponding increase in empty lacunae when compared to
nonradiated fractures (p5 .001). With the addition of DFO, these differ-
ences were not appreciated. Further, a 42% increase in bony unions
was observed after DFO therapy.
Conclusion. Targeting angiogenesis is a useful means for promoting
osteocyte survival and preventing bone pathology after XRT. VC 2014
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INTRODUCTION
Over 53,000 men and women were diagnosed with head
and neck cancers and an additional 11,000 patients died
from complications relating to these cancers in 2012.1
Radiation therapy (XRT) is a standard adjuvant therapy
for patients with head and neck cancer, and while the
delivery of this treatment has become more precise with
the development of intensity-modulated XRT,2,3 the per-
nicious effects of XRT on normal, healthy tissues remains
a concern. The population of cancer survivors who
develop osteoradionecrosis (ORN), pathologic fractures,
and subsequent nonunions after XRT experience a dimin-
ished quality of life. Their ability to eat, drink, speak, and
socialize may be enormously impacted by the deleterious
side effects of this necessary but destructive therapy. Fre-
quently, ORN is a late finding and inciting event to path-
ologic fractures and associated nonunions. A therapeutic
means designed to prevent this progression would there-
fore be highly desirable.
Deferoxamine (DFO) is a widely utilized iron chelator,
currently on formulary for the treatment of iron toxicity.4
DFO is generally well-tolerated, with only minor side
effects, such as mild nausea and discomfort.5–7 In addi-
tion to the utility of DFO as an iron chelator, it has also
demonstrated the potential to upregulate angiogenesis via
the stimulation of the hypoxia-inducible factor-1-alpha
pathway. When given in minute, localized intermittent
doses, DFO induces vascular endothelial growth factor
production, in addition to other mediators of angiogenesis,
resulting in the augmentation of resident vasculature and
the production of new blood vessels.8 Furthermore, inves-
tigators have recently demonstrated that triggering an
upregulation of vascular endothelial growth factor directly
stimulates osteogenesis, at comparable levels to bone
morphogenic protein 2 in vivo.9–12
Although the majority of DFO research has been in the
context of long bone animal models, previous work in
our laboratory has demonstrated the ability of DFO to
augment the vascular networks of irradiated mandibles
after fracture repair.13,14 The purpose of this project was
to examine the ability of DFO to replenish the cellular
environment of these irradiated mandibles through the
metrics of histologic analysis. We posit that DFO will
increase bone cellularity and ameliorate osteocyte func-
tion, leading to a marked improvement in overall bone
healing after XRT.
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MATERIALS AND METHODS
Experimental design
Animal experimentation was performed in compliance
with the guidelines published in the Guide for the Care
and Use of Laboratory Animals: Eighth Edition, ISBN-
10: 0-309-15396-4. Our protocols were approved by the
University of Michigan’s Committee for the Utilization
and Care of Animals before implementation. Thirty-five
adult male Sprague Dawley rats (400 g) were paired in
cages in a specific pathogen-free vivarium and maintained
on a 12-hour light/dark cycle. Before irradiation, the rats
had a 7-day acclimation period. The animals were ran-
domly assigned into 3 groups, each undergoing fracture
repair. Group 1 (n5 11; Fx) served as our control fracture
repair group, undergoing only the osteotomy. Group 2
(n5 12; XFx) received XRT 2 weeks before the osteot-
omy surgery. Group 3 (n5 12; XFxDFO) received XRT,
underwent osteotomy surgery 2 weeks later, and was then
administered DFO treatment.
Irradiation protocol
All radiation was performed in the Irradiation Core in
the University of Michigan Department of Radiation
Oncology. After induction of anesthesia via an oxygen/
isoflurane mixture, left hemimandibles were irradiated
using a Philips RT250 orthovoltage unit (250 kV X-rays,
15 mA; Kimtron Medical, Woodbury, CT). The animals
were administered ionizing radiation through a filtered
system to our specific region of interest (ROI), which
spans a 2 mm distance posterior to the third molar, corre-
sponding to the future site of the osteotomy. Localized
delivery was ensured by using a lead shield placed over
the rat exposing only our ROI. A human-equivalent dose
of radiation, developed with the guidance of the Depart-
ment of Radiation Oncology, was utilized. A fractionated
dose of 7 Gy per day was administered over 5 days for a
total of 35 Gy. This is equivalent to 70 Gy in human
mandibular high-dose XRT, which was used to predict-
ably replicate the pathologies similar to those seen in the
setting of clinically advanced mandibular ORN.15–17
Perioperative care
Rats were administered gentamicin (5 mg/kg SQ) once
before surgery and twice postoperatively. For analgesia,
rats were administered buprenorphine (0.03 mg/kg SQ) in
lactated Ringer’s solution (25 mL/kg). Animals were
anesthetized using an oxygen-isoflurane mixture. Postop-
eratively, animals were administered buprenorphine twice
daily through postoperative day 5, and as needed there-
after. Weight gain, porphyrin staining, and fluid intake
were monitored to determine the need for continued
analgesia.
Surgical procedure
After sterile preparation and draping, a 2 cm midline
incision was placed ventrally from the anterior submen-
tum to the neck crease. An external fixator device was
placed and secured, as previously described in the litera-
ture.18 A vertical osteotomy was performed directly
behind the third molar of the left hemimandible using a
reciprocating saw blade. A fixed 2 mm fracture gap was
set 4 hours postoperatively by turning the fixator screw
clockwise a total of 7 times. This gap ensures a grossly
visible separation that can be later sectioned and analyzed
histologically. After a 40-day healing period, the animals
were euthanized and left hemimandibles were harvested
for union analysis and histologic processing. Union was
defined as gross bony bridging with the absence of
motion across the fracture site after fixator removal. Of
note, we experienced 1 fatality during the surgical proce-
dure, resulting in the loss of 1 animal from the Fx group.
Deferoxamine dosing
The DFO-treated group was administered localized
injections (200 mmol/300 mL) directly into the fracture site
every other day from postoperative day 4 to 12 for a total
of 5 doses. This time period was selected to coincide with
the initiation of angiogenesis in a murine fracture model.19
Histologic processing
After the 40-day fracture healing period, the mandibles
were fixed with 70% ethanol, and subsequently rinsed in
phosphate-buffered saline. The samples were then decalci-
fied using Cal-ExII (10.6% formic acid, 7.4% formalde-
hyde, <1% methyl alcohol; Fisher Scientific, Fair Lawn,
NJ) and stored at 4C. The solution was changed daily
and total decalcification was confirmed radiographically
using a self-contained Faxitron X-Ray device (MX20;
Faxitron X-Ray, Lincolnshire, IL). The samples were vac-
uum processed (dehydration and paraffin infiltration)
under a 48-hour program in a Hypercenter tissue proces-
sor (Hypercenter XP; Shandon, Pittsburg, PA), then fil-
trated once more for 2 hours in a vacuum bath. They
were subsequently embedded in Paraplast Plus (McCor-
mic Scientific; Richmond, IL) in 22- 3 40-mm peel-away
molds and stored overnight at 4C. The blocks were sec-
tioned coronally from anterior to posterior into 7-micron
thick sections taken on a Leica Richert–Jung microtome
(model 2030; Biocut, Bensheim, Germany), and mounted
on glass slides. The sections were surface-stained with
Gomori’s trichrome.
Histomorphometric evaluation
In order to count the number of osteocytes and empty
lacunae, we utilized a light microscope interfaced with a
camera linked to a computer. Our ROI spanned a distance
of 2 mm posterior to the third molar, encompassing the
site of fracture repair. The ROI was superimposed on the
digital image using Bioquant NOVA Osteo version 7
imaging analysis software (R&M Biometrics, Nashville,
TN). Nine high-power-field images were selected at ran-
dom for each ROI using 163 magnification. Three
reviewers independently performed the point counting of
osteocytes and empty lacunae.
Thresholding evaluation
Digital images of each slide were loaded onto the pre-
viously mentioned Bioquant software package in order to
measure the tissue volume and osteoid volume of each
sample. Mature bone stained blue and immature bone
stained pink, allowing for easy distinction during the
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thresholding process. The software calculated the osteoid
volume/tissue volume ratio, which indicates the percent-
age of nonmineralized, immature bone in our ROI.
Statistical analysis
All data is presented as the mean6 SD. Values were
analyzed with a 1-way analysis of variance (ANOVA)
using PSAW for Windows version 21.0 (SPSS, Chicago,
IL). Significance was assigned as p< .05.
RESULTS
Histomorphometric analysis
As expected, histologic analysis revealed a significant
decrement in osteocyte number in the radiated group as
compared to the Fx group (29.766 10.83 vs 69.486
10.86; p5 .01; see Figure 1). We also saw a significant
restoration in osteocyte count from the radiated group to
the DFO-treated group (29.766 10.83 vs 66.246 6.36;
p5 .01). Interestingly, DFO treatment also demonstrated
no significant difference in osteocyte count from the Fx
group (66.246 6.36 vs 69.486 10.86; p5 .67), indicating
a restoration to control level osteocyte viability (see
Figure 2).
Similarly, further histologic analysis revealed a signifi-
cant increase in empty lacunae number in the radiated
group as compared to the Fx group (7.206 3.86 vs
2.116 0.98; p5 .002; see Figure 3). The number of
empty lacunae is a corroborating metric indicating osteo-
cyte death; therefore, a decreased osteocyte count
FIGURE 1. From left to right, fracture group (Fx), radiated group (XFx) and deferoxamine-treated group (XFxDFO). Digital photograph stained with
Gomori’s trichrome at 163 magnification demonstrating DFO-treated restoration of osteocyte count and osteoid (pink). Note the comparative
depletion of osteocytes and increase in empty lacunae in the radiated group (center). [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
FIGURE 2. Osteocyte count per high power field means and SDs
for the fracture group (Fx), radiated group (XFx), and
deferoxamine-treated group (XFxDFO). *Denotes significance at
p< .05 between means. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
FIGURE 3. Empty lacunae count per high power field means and
SDs for the fracture group (Fx), radiated group (XFx), and
deferoxamine-treated group (XFxDFO). *Denotes significance at
p< .05 between means. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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typically correlates with an increase in empty lacunae, as
seen in our XFx group. We also saw a corresponding sig-
nificant decrease in empty lacunae when comparing XFx
to XFxDFO (7.206 3.86 vs 2.976 1.41; p5 .008).
Again, DFO treatment decreased the number of empty
lacunae to levels that were not significantly different
from the Fx group (2.976 1.41 vs 2.116 0.98; p5 .23),
indicating a restoration to control levels.
Thresholding analysis
The osteoid volume/tissue volume in the ROI
was found to be significantly lower in the XFx group
when compared to the Fx group (15.2%6 6.9% vs
35.4%6 14.1%; p5 .001; see Figure 4). Treatment with
DFO showed a significant improvement in the osteoid
volume/tissue volume ratio as compared to the XFx group
(26.9%6 12.6% vs 15.2%6 6.9%; p5 .045). In accord-
ance with our hypothesis, the osteoid volume/tissue vol-
ume ratio for the group treated with DFO was not
significantly different from the Fx group (35.4%6 14.1%
vs 26.9%6 12.6%; p5 .203), indicating a restoration to
control levels (see Figure 1).
Bony union
After a 40-day recovery period, the Fx mandibles
demonstrated complete bony union in 100% (all of
11) of specimens, as expected. With the addition of
XRT, XFx mandibles only exhibited a 25% (3 of 12)
union rate. The treatment of radiated fractures with
DFO increased the rate of bony union to 67%, (8 of
12), indicating a marked improvement from the XFx
group.
Qualitative assessments
We observed decreased hematopoietic cellularity (see
Figure 5) and periosteal fibrosis and detachment, consist-
ent (see Figure 6) with radiation damage in our XFx
group. These changes were not observed in the XFxDFO
group, indicating a preservation of hematopoietic cellular-
ity and periosteal attachment. In addition, nuclear
changes, such as karyolysis (fading), pyknosis (shrink-
age), and karyorrhexis (fragmentation) were seen in the
XFx group (see Figure 7). These changes were visibly
reduced in the XFxDFO group, indicating a preservation
of nuclear integrity.
DISCUSSION
The effects of XRT on bone tissue are often not appre-
ciated until cumulative tissue damage leads to functional
and mechanical failures requiring surgical intervention.
Ascertaining the optimal time point when tumor recur-
rence is minimal and mechanical failure has not yet
FIGURE 4. Ratio of nonmineralized, immature bone in the region
of interest (ROI; osteoid volume/tissue volume) means and SDs
for the fracture group (Fx), radiation group (XFx), and
deferoxamine-treated group (XFxDFO). *Denotes significance at
p< .05 between means. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
FIGURE 5. Digital photograph stained with Gomori’s trichrome at 163 magnification demonstrating clotting, cellular fibrosis, and depletion of cellu-
larity in the hematopoietic cavities observed in the radiation group (XFx) group (left), which is not evident in the deferoxamine-treated group
(XFxDFO) specimen (right). Note the marrow cavities teeming with viable, robust hematopoietic cells in the DFO-treated mandibles in contradistinc-
tion. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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ensued would serve as a window of opportunity for thera-
pies designed to reverse the underlying effects of radia-
tion on bone. We have previously established a rat model
of pathologic fracture healing after XRT whereby nonun-
ions consistently developed in 75% to 80% of cases.13,14
Admittedly, this model does not take into account any
oncologic incidence or progression; however, it does give
us a platform whereby we can examine and quantify
mechanical failure in the form of failed bony union in
response to the aberrant effects of radiation on bone heal-
ing. Previous work in our laboratory has quantifiably
demonstrated the ability of DFO to augment the
vascularity, mineralization, and mechanical strength of
fracture healing in this model, and this communication
FIGURE 6. Digital photograph stained with Gomori’s trichrome at 163 magnification demonstrating periosteal fibrosis and detachment in the radia-
tion group (XFx) group (left), which is not evident in the deferoxamine-treated group (XFxDFO) specimen (right). [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
FIGURE 7. Digital photograph
stained with Gomori’s trichrome
at 163 magnification demon-
strating nuclear fading (upper
left arrow), shrinkage (middle
left arrow), and fragmentation
(bottom left arrow) in the radia-
tion group (XFx) group. The
deferoxamine-treated group
(XFxDFO) group (right) contains
robust nuclei in the osteocytes.
[Color figure can be viewed in
the online issue, which is avail-
able at wileyonlinelibrary.com.]
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specifically examines the effect of osteocyte survival and
function within this context.
In this study, we observed significant quantifiable
depletions in histologic metrics after radiated fracture
healing that were restored to control levels with the addi-
tion of DFO therapy. In particular, DFO demonstrated the
capability to produce significantly higher osteocyte counts
and lower empty lacunae levels than the XFx group. In
addition, osteocyte counts and empty lacunae values were
not significantly different from Fx controls, suggesting
that DFO has the ability to restore cellularity to levels
expected during normal fracture healing in nonradiated
bone.
Histologically, osteoid is the unmineralized, organic
portion of bone matrix. Osteoid is formed by functional
osteoblasts before subsequent mineralization and succes-
sion to mature bone tissue. Our thresholding analysis
revealed a severe restriction in the ability of radiated
bone to produce osteoid. This effect was not observed in
DFO-treated mandibles. In fact, DFO-treated mandibles
exhibited osteoid volume/tissue volume ratios that were
not statistically different than control, supporting our
hypothesis that an indirect effect on therapeutic vascular
augmentation played a critical role in restoring early bone
production. Qualitative findings also afforded unique
insights into the overall histologic effects of DFO in pre-
venting radiation-induced damage. We observed structural
damage consisting of hematopoietic cell depletion, perios-
teal fibrosis and detachment, and nuclear changes because
of XRT that were not evident in DFO-treated mandibles.
Ultimately, these findings amalgamated to a clinically
relevant increase in the rate of bony union, as DFO-
treated mandibles exhibited a 2.5-fold increase in the rate
of bone union despite exposure to XRT.
Undoubtedly, using an angiogenic therapeutic strategy
in an area of previous malignancy raises concerns. Some
authors have even suggested the utility of antiangiogenic
agents as antitumor treatments.20,21 However, although
we did not take into account the tumorigenicity of DFO,
there is evidence that DFO may, in fact, have antitumori-
genic properties. Studies by Kulp et al22 and Hann et al23
suggest that DFO promotes apoptosis and decreased sur-
vival in p531 tumor cells, as well as deprives hepatocel-
lular carcinoma cells of the iron stores necessary for
DNA replication. Further, Lee et al24,25 report evidence
demonstrating the antitumorigenic effect of DFO in in
vitro studies of oral keratinocytes. His studies suggest
growth arrest and cytochrome c-dependent apoptosis in
immortalized and malignant oral keratinocytes. Although
our studies are not particularly concerned with the possi-
bility of treating oral cancers with DFO, their studies lend
important evidence for suggesting the potentially safe and
efficacious use of DFO at a remote time from oncologic
management.
Taken together, we support the continued investigation
of this promising therapy for its potential optimization
and use in the head and neck cancer population for the
prevention and treatment of pathologic fractures and non-
unions because of XRT. Further, we argue that the surgi-
cal removal of tumor, subsequent radiation, and the
temporal distance from oncologic management to the tim-
ing of the development of bone pathologies favor the
potential use of this therapy at a remote time from onco-
logic management that precedes the events of mechanical
failure.
CONCLUSIONS
This study demonstrates that DFO replenishes osteocyte
count, reverses tissue damage, and increases union rate
after XRT in a model of mandibular pathologic fracture
repair. Future directions include combining DFO therapy
with radioprotectants or stem cell therapies to further
delineate the optimum regimen to improve fracture site
cellularity and healing. Because of its clinical applicabil-
ity and outlet for future research, DFO is a promising
option for the prevention and treatment of pathologic
fractures and nonunions associated with XRT.
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